Square-backed event ticketing management platform Eventbrite will price its shares between $19 and $21 and could raise up to a total of more than $241m when it goes public.

Boston Scientific will pay $500m upfront and up to $100m in milestone payments to acquire Augmenix, providing exits to Varian Medical Systems and Ascension Health.

Logistics data analytics platform Locix has emerged from stealth with $20m in funding provided by investors including University of Tokyo Edge Capital.

Medison Ventures was among the participants in a round that will fund clinical tests for Alpha Tau's radiation-based cancer treatment.

Existing backers AstraZeneca and Johnson & Johnson returned for a round that will advance PhaseBio's orphan disease drug pipeline, based on research from Duke University.

The cancer therapy developer has secured $120m in a convertible note offering featuring the University of California office of the chief investment officer.

Existing backers AstraZeneca and Johnson & Johnson returned for a round that will advance PhaseBio's orphan disease drug pipeline.

The Pfizer-backed cancer therapy developer has secured $120m in a convertible note offering led by Perceptive Advisors.

The Alphabet and Roc Nation-backed trading platform is gearing up to go public after achieving a $5.6bn valuation earlier this year.